DELCATH SYSTEMS IN (DCTH)

0.02
OTC Markets
Prev Close 0.02
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.02 / 127.72
Exchange OTC Markets
Shares Outstanding 434.98B
Market Cap 8.26M
Div & Yield N.A. (N.A)

Latest News

Delcath Issues Letter To Shareholders

Delcath Issues Letter To Shareholders

Delcath Announces Relisting On OTCQB

Delcath Announces Relisting On OTCQB

Company to Ensure Orderly Transition from NASDAQ to OTC Market

Delcath Issues Letter To Stockholders

Delcath Issues Letter To Stockholders

Delcath Issues Letter To Stockholders

Delcath Announces 2016 Financial Results

Delcath Announces Special Protocol Assessment Agreement With FDA For Pivotal Trial With Melphalan/HDS In Intrahepatic Cholangiocarcinoma

Company Plans to file 2016 Fourth Quarter and Year End Financial Results by March 30, 2017

Published Review Shows Delcath Investigational PHP Doubles Overall Survival Over Other Targeted Liver Therapies

Single-Center Retrospective Data Also Demonstrate Therapy Extends Progression-Free Survival by 9 Months

Analysis From Two Institutions Shows Strong Tumor Response, Overall Survival Potential Of Delcath Investigational PHP Therapy

Retrospective Analysis of Outcomes with Investigational Melphalan/HDS and Commercial CHEMOSAT® Projects Median Overall Survival to be 657 Days; 1,207 Days for Responders

Delcath Prices Underwritten Public Offering Of Common Stock And Warrants

Delcath Prices Underwritten Public Offering Of Common Stock And Warrants

Delcath Systems, Inc. (DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced the pricing of an underwritten public offering of 425,000...

Data Supporting CHEMOSAT Presented At The Cardiovascular And Interventional Radiology Society Of Europe Conference

Data Supporting CHEMOSAT Presented At The Cardiovascular And Interventional Radiology Society Of Europe Conference

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on developing safe and effective treatments for primary and metastatic liver cancers, announces that results from two single-institution...

3 Breakout Stocks Under $10 to Trade Now

3 Breakout Stocks Under $10 to Trade Now

These under-$10 stocks are within range of triggering breakout trades.

Delcath Systems (DCTH) Weak On High Volume

Delcath Systems (DCTH) Weak On High Volume

Trade-Ideas LLC identified Delcath Systems (DCTH) as a weak on high relative volume candidate

5 Active Under-$10 Stocks to Buy Now

5 Active Under-$10 Stocks to Buy Now

When a stock makes a large move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Northwest Bio's German Smokescreen Obscures DCVax Problems

Northwest Bio's German Smokescreen Obscures DCVax Problems

Northwest Bio received good news from Germany in February but didn't tell investors until Monday.